184 related articles for article (PubMed ID: 9052903)
1. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
[TBL] [Abstract][Full Text] [Related]
2. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
[TBL] [Abstract][Full Text] [Related]
3. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease.
Sramek JJ; Hurley DJ; Wardle TS; Satterwhite JH; Hourani J; Dies F; Cutler NR
J Clin Pharmacol; 1995 Aug; 35(8):800-6. PubMed ID: 8522637
[TBL] [Abstract][Full Text] [Related]
4. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR; Peters D; Sparks RG
CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
[TBL] [Abstract][Full Text] [Related]
5. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM
Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749
[TBL] [Abstract][Full Text] [Related]
6. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
[TBL] [Abstract][Full Text] [Related]
7. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dubé S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC
Am J Psychiatry; 2008 Aug; 165(8):1033-9. PubMed ID: 18593778
[TBL] [Abstract][Full Text] [Related]
8. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.
Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM
Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
Veroff AE; Bodick NC; Offen WW; Sramek JJ; Cutler NR
Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):304-12. PubMed ID: 9876958
[TBL] [Abstract][Full Text] [Related]
10. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
[TBL] [Abstract][Full Text] [Related]
12. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.
Satlin A; Bodick N; Offen WW; Renshaw PF
Am J Psychiatry; 1997 Oct; 154(10):1459-61. PubMed ID: 9326834
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline.
Wang D; Yang L; Su J; Niu Y; Lei X; Xiong J; Cao X; Hu Y; Mei B; Hu JF
Biochem Biophys Res Commun; 2011 Jul; 410(2):229-34. PubMed ID: 21651893
[TBL] [Abstract][Full Text] [Related]
14. Classics in Chemical Neuroscience: Xanomeline.
Bender AM; Jones CK; Lindsley CW
ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924
[TBL] [Abstract][Full Text] [Related]
15. M
Russell JK; Ingram SM; Teal LB; Lindsley CW; Jones CK
ACS Chem Neurosci; 2023 Feb; 14(3):435-457. PubMed ID: 36655909
[TBL] [Abstract][Full Text] [Related]
16. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
Shannon HE; Bymaster FP; Calligaro DO; Greenwood B; Mitch CH; Sawyer BD; Ward JS; Wong DT; Olesen PH; Sheardown MJ; Swedberg MD; Suzdak PD; Sauerberg P
J Pharmacol Exp Ther; 1994 Apr; 269(1):271-81. PubMed ID: 7909557
[TBL] [Abstract][Full Text] [Related]
17. Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells.
DeLapp N; Wu S; Belagaje R; Johnstone E; Little S; Shannon H; Bymaster F; Calligaro D; Mitch C; Whitesitt C; Ward J; Sheardown M; Fink-Jensen A; Jeppesen L; Thomsen C; Sauerberg P
Biochem Biophys Res Commun; 1998 Mar; 244(1):156-60. PubMed ID: 9514902
[TBL] [Abstract][Full Text] [Related]
18. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
Christopoulos A; Pierce TL; Sorman JL; El-Fakahany EE
Mol Pharmacol; 1998 Jun; 53(6):1120-30. PubMed ID: 9614217
[TBL] [Abstract][Full Text] [Related]
19. Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
Breier A; Brannan SK; Paul SM; Miller AC
Psychopharmacology (Berl); 2023 May; 240(5):1191-1198. PubMed ID: 37036495
[TBL] [Abstract][Full Text] [Related]
20. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
Vamvakidès A
Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
